V Square Quantitative Management LLC Grows Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

V Square Quantitative Management LLC lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 21.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,802 shares of the company’s stock after purchasing an additional 3,549 shares during the period. V Square Quantitative Management LLC’s holdings in Teva Pharmaceutical Industries were worth $439,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of TEVA. Stifel Financial Corp lifted its holdings in Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after purchasing an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after buying an additional 33,277 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after buying an additional 40,218 shares during the period. Sio Capital Management LLC purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $24,314,000. Finally, CWA Asset Management Group LLC bought a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $3,340,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $16.24 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $18.39 billion, a P/E ratio of -11.20, a PEG ratio of 1.39 and a beta of 0.71. The stock has a 50-day moving average price of $19.96 and a 200-day moving average price of $18.50. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Analyst Ratings Changes

TEVA has been the subject of several recent research reports. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Barclays cut their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.